About Passage Bio, Inc.
https://www.passagebio.comPassage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases.
CEO
William Chou
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-07-14 | Reverse | 1:20 |
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
HIGHLINE CAPITAL MANAGEMENT, L.P.
Shares:1.24M
Value:$18.74M
BLACKROCK INC.
Shares:817.53K
Value:$12.39M
LYNX1 CAPITAL MANAGEMENT LP
Shares:623.7K
Value:$9.46M
Summary
Showing Top 3 of 15
About Passage Bio, Inc.
https://www.passagebio.comPassage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $8.65M ▼ | $-7.75M ▲ | 0% | $-2.45 ▲ | $-7.44M ▲ |
| Q2-2025 | $0 | $10.13M ▼ | $-9.38M ▲ | 0% | $-2.96 ▲ | $-9.19M ▲ |
| Q1-2025 | $0 | $16.46M ▲ | $-15.4M ▼ | 0% | $-4.96 ▼ | $-13.62M ▼ |
| Q4-2024 | $0 | $13.55M ▼ | $-12.72M ▲ | 0% | $-4.1 ▲ | $-12.31M ▲ |
| Q3-2024 | $0 | $20.7M | $-19.34M | 0% | $-6.26 | $-15.15M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $52.77M ▼ | $74.16M ▼ | $43.04M ▲ | $31.12M ▼ |
| Q2-2025 | $57.63M ▼ | $79.2M ▼ | $40.94M ▲ | $38.26M ▼ |
| Q1-2025 | $63.36M ▼ | $86.01M ▼ | $39.3M ▼ | $46.71M ▼ |
| Q4-2024 | $76.76M ▼ | $102.41M ▼ | $41.15M ▲ | $61.26M ▼ |
| Q3-2024 | $84.83M | $111.75M | $39.04M | $72.72M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-7.75M ▲ | $-4.85M ▲ | $0 ▼ | $0 ▼ | $-4.85M ▲ | $-4.85M ▲ |
| Q2-2025 | $-9.38M ▲ | $-6.33M ▲ | $585K ▼ | $14K ▲ | $-5.73M ▼ | $-6.33M ▲ |
| Q1-2025 | $-15.4M ▼ | $-13.85M ▼ | $39.63M ▲ | $0 ▼ | $25.78M ▲ | $-13.85M ▼ |
| Q4-2024 | $-12.72M ▲ | $-8.44M ▼ | $13.68M ▼ | $47K ▲ | $5.28M ▼ | $-8.46M ▼ |
| Q3-2024 | $-19.34M | $-7.45M | $14.97M | $0 | $7.52M | $-7.47M |
CEO
William Chou
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-07-14 | Reverse | 1:20 |
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
HIGHLINE CAPITAL MANAGEMENT, L.P.
Shares:1.24M
Value:$18.74M
BLACKROCK INC.
Shares:817.53K
Value:$12.39M
LYNX1 CAPITAL MANAGEMENT LP
Shares:623.7K
Value:$9.46M
Summary
Showing Top 3 of 15